IJC Heart Vasculature 14 2017 1419 Contents lists available ScienceDirect IJC Heart Vasculature j o u r n l h o m e p g e h t t p w w w j o u r n l s e l s e v e r c o m j c h e r t n d v s c u l t u r e Dipyridamoleinduced adverse effects myocardial perfusion scans Dynamic evaluation SinDi Lee WeiChun Huang bcd NanJing Peng ab Chin Hu Department Nuclear Medicine Kaohsiung Veterans General Hospital Kaohsiung Taiwan b School Medicine National YangMing University Taipei Taiwan c Section Critical Care Cardiovascular Medical Center Kaohsiung Veterans General Hospital Kaohsiung Taiwan d Department Physical Therapy Fooyin University Kaohsiung Taiwan r t c l e n f o b s t r c t Article history Received 26 July 2016 Accepted 19 November 2016 Available online 27 November 2016 Keywords Dipyridamole Myocardial perfusion scan Adverse effects Aim Background Dipyridamoleinduced stress myocardial perfusion scans MPS widely management coronary artery disease The adverse effects dipyridamole stress agents evaluated The aim research conﬁrm dynamic data dipyridamole effects MPS Methods We collected data 183 patients underwent dipyridamoleinduced stress MPS retrospectively reviewing clinical records included severity dipyridamole effects 3 min 10 min 20 min infusion The incidence severity points including effect age gender obtained Results Adverse effects occurred 96 patients 696 The frequent symptoms dizziness 428 chest tightness 246 abdominal pain 181 headache 152 Most symptoms Grade 1 2 ac cording grading common terminology criteria The median duration symptom persistence 36 min signiﬁcantly different age gender Conclusion This study demonstrates adverse effects dipyridamole generally minimal du ration acceptable clinical usage 2016 The Authors Published Elsevier Ireland Ltd This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 1 Introduction Cardiovascular disease second common mortality 2000 Taiwan 1 Myocardial perfusion imaging MPI useful tool diagnosing follow care coronary artery disease 2 Ac cording current clinical guidelines better sensitivity speciﬁci ty exam performed stress test 24 Dipyrdamole vasodilator widely agents stress tests Taiwan According prior literature 70 patients undergoing dipyridamole stress suffer adverse effects ﬂush chest pain headache dizziness hypotension abdominal pain diarrhea 59 However severity duration adverse effects analyzed As stated aim study examine dynamic data dipyridamole effects MPS Corresponding author Email addresses mcdleegmailcom sdleevghksgovtw SD Lee 2 Materials methods 21 Patients data collection In institute symptoms patients receiving dipyridamolestress MPI 3 min 10 min 20 min recorded according Com mon Terminology Criteria Adverse Effects v40 CTCAE 10 Records written maintained physicians technicians Symptoms recorded included chest tightness palpitation abdominal pain diar rhea nausea headache dizziness neck pain dyspnea weakness ﬂush If symptoms persisted 20 min administration recorded timing recovery In case aminophylline use lieve adverse effects recorded administration timing From July 2nd 2013 July 19th 2013 183 patients ceiving MPI There 138 complete records symptoms deliv ery dipyridamole For evaluation confounding factors collected following parameters age gender frequency regu lar exercise These comorbidities recorded clinical chart view hypertension diabetes dyslipidemia prior myocardial infarction MI documented coronary artery disease CAD congestive httpdxdoiorg101016jijcha201611002 23529067 2016 The Authors Published Elsevier Ireland Ltd This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 SD Lee et al IJC Heart Vasculature 14 2017 1419 15 heart failure The laboratory data 3 months recorded creatinine level lipid proﬁle hepatic enzyme glutamate pyruvate transaminase GPT These methods approved institutional review board 22 Stress protocol All patients underwent Thallium201 Tl201 stress early redistribution MPI dipyridamole stress test recommen dation Society Nuclear Medicine Molecular Imaging SNMMI EANM Heart rate blood pressure ECG monitoring performed stress test 23 Statistics R project version 312 statistical analysis The continu ous parameters expressed terms mean standard deviation SD The categorical variables expressed count percentage Severity symptom 3 min 10 min 20 min expressed count percentage The KaplanMeier curve highlight persistent symptoms Patients groups according age age N65 For eval uation confounding factors gender age KaplanMeier curve Cox regression test comparison males females age groups exercise groups 3 Results Data 138 patients analyzed listed Table 1 The av erage age 661 134 years range 3290 Seventyﬁve male 543 60 study subjects exercised 3 times week 435 There 96 patients 696 suffering symptoms drug effects observation Between symptomatic asymptomatic group incidence comorbidities lab data statistically different serum creatinine level Table 2 Number percentage symptoms 3 10 20 min 3rd minute 10th minute 20th minute Any time Chest tightness Palpitation Abdominal pain Dyspnea Diarrhea Nausea Headache Dizziness Neck pain Weakness Flush Overall 26 188 4 29 13 94 10 73 0 5 36 16 116 52 377 5 36 3 22 3 22 84609 24 174 2 14 19 138 7 51 0 7 51 13 94 45 326 5 36 6 43 1 07 79 572 17 123 2 14 7 51 4 29 0 7 51 11 80 30 217 8 58 7 51 1 07 56 406 34 246 5 36 25 181 12 87 0 11 80 21 152 59 428 10 72 7 51 4 29 96 696 higher asymtomatic group However symptomatic group ratio female patients signiﬁcantly higher asymp tomatic group p 0002141 age signiﬁcantly younger p 0009262 The frequency severity adverse effects listed Table 2 Fig 1 Adverse effects occurred 96 patients 696 fre quent symptoms dizziness 428 chest tightness 246 ab dominal pain 181 headache 152 These effects accompany dyspnea 87 nausea 80 neck pain 72 weakness 51 pal pitation 36 ﬂush 29 No patients diarrhea study population symptoms Grade 1 2 Seven patients Grade 3 symptoms shown Table 6 There 18 patients ceiving aminophylline treatment adverse effects For patients symptoms 3 min persistent symptoms seen KaplanMeier curve Fig 2 The median duration persistent symp toms 36 min 95 conﬁdence interval CI 3046 min Fiftysix patients 406 recover effects 20 min 32 female Table 1 Patient background information Number Gender Male Female Age years old Frequency exercise times week Range Median Mean 3 Using aminophylline Timing min Comorbidity Hypertension Diabetes Dyslipidemia Prior MI Documented CAD Congestive heart failure Creatinine n 125 HDL n 111 LDL n 111 TG n 106 GPT n 119 Pretest SBP Pretest DBP Post test SBP Post test DBP Total 138 75 543 63 457 661 134 3290 07 1 28 60 435 18 222 85 85 616 37 268 51 370 22 159 39 283 10 72 137 107 057687 4031 1052 1977 9752 2916 41218 15595 11354 35769 2977 2698 4261 15095 22 101214 8688 123 57126 1308 1827 94188 7521 1187 49113 Symptomatic 96 41 427 55 573 642 1324 3290 Asymptomatic 42 33 786 9 214 706 1288 4190 Pvalue 0002141 0009262 29 25 04626 56 583 24 250 34 354 14 146 23 240 7 73 119 077 057669 4083 1083 2277 9717 2707 41195 16207 10849 4269 2966 177 6101 15025 2332 101214 8687 1343 57126 13202 1937 94188 758 1237 52113 29 690 13 310 17 405 8 190 16 381 3 71 179 149 081606 3917 988 1959 9829 3369 48218 14242 12468 35552 3003 4148 4261 15257 1882 110183 8690 940 71106 12802 1529 94164 7386 11065 4995 0317 06048 07077 06844 01358 1 002368 04284 08642 0438 09597 05392 09876 01971 03505 16 SD Lee et al IJC Heart Vasculature 14 2017 1419 Fig 1 Severity adverse effects dipyridamole infusion 3 different points Grading based CTCAE v40 There signiﬁcantly higher incidence adverse effects female population male population points Tables 1 3 There higher incidence women time points dizziness chest tightness abdominal pain headache dyspnea nau sea weakness palpitation However signiﬁcant difference genders dizziness 10 min There signiﬁcant difference symptom duration genders Fig 3 p value Cox regression 0421 The median time symptomrelief took 33 min women 36 min men Women tend higher incidence adverse effects severe symptoms There signiﬁcant difference dizziness groups 10 min p 0003724 Younger patients age b 65 tended higher probability adverse effects older patients statistically sig niﬁcant difference 3 min Table 4 The younger group greater risk symptoms dizziness Symptom duration similar Fig 2 For patients symptoms 3 min persistence shown KaplanMeier curve age groups Fig 4 p 0374 The median time symptomrelief took 33 min older people 48 min younger peo ple Younger people higher incidence adverse effects severe symptoms There signiﬁcant difference chest tightness nausea groups 3 min p 0000162 Exercise interfere adverse dipyridamole effects study See Table 5 4 Discussion The purpose MPI stress test induce distinction blood ﬂow normal coronary arteries stenosis Dipyridamole pharmaceutical method stress testing Dipyridamole infusion blocks reabsorption metabolism endogenic adenosine 1112 elevates extracellular adenosine concentration 1213 nonselectively activates types adenosine receptors 12 induces vascular resistance normal coronary artery decrease creates myocardial blood ﬂow increase 5fold 1113 On hand blood ﬂow myocardium supplied stenosed coronary arteries unable increase blood ﬂow stress compensatory dilation rest 11 12 Dipyridamolestress MPI able detect coronary artery disease accurately exercise stress tests provides prognostic informa tion cardiac death myocardial infarction 11 Using dipyridamole myocardial perfusion generally safe 58 1314 Nevertheless 70 patients undergoing dipyridamole stress suffer variable adverse effects ﬂush chest pain headache dizziness hypotension abdominal pain diarrhea 59 Adverse effects develop stimulating different types adeno sine receptors signal pathways including peripheral vasodilation hypotension 12 In study population 696 patients suffered adverse effects dipyridamole The frequent symptoms dizziness chest tightness abdominal pain headache Prior literature shows incidence adverse effects dipyridamole range 279 7536 5791517 However wide variation deﬁnition adverse effects studies Table 3 Incidence symptomatic patients 3 10 20 min gender Table 4 Incidence symptomatic patients 3 10 20 min age SD Lee et al IJC Heart Vasculature 14 2017 1419 17 Male n 75 Female n 63 p value 3rd minute Chest tightness Palpitation Abdominal pain Dyspnea Diarrhea Nausea Headache Dizziness Neck pain Weakness Flush 10th minute Chest tightness Palpitation Abdominal pain Dyspnea Diarrhea Nausea Headache Dizziness Neck pain Weakness Flush 20th minute Chest tightness Palpitation Abdominal pain Dyspnea Diarrhea Nausea Headache Dizziness Neck pain Weakness Flush Any time Chest tightness Palpitation Abdominal pain Dyspnea Diarrhea Nausea Headache Dizziness Neck pain Weakness Flush 35 467 10 133 1 13 6 80 3 40 0 1 13 7 93 24 320 1 13 0 2 27 32 427 10 133 1 13 8 107 1 13 0 2 27 6 80 16 213 3 40 1 13 1 13 24 320 7 93 1 13 1 13 1 13 0 2 27 5 67 12 160 4 53 2 27 0 42 560 14 187 2 27 11 147 3 40 0 3 40 8 107 25 333 4 53 2 27 2 27 49 778 16 254 3 48 7 111 7 111 0 4 63 9 143 27 429 4 63 3 48 1 16 46 730 14 222 1 16 11 175 6 95 0 5 79 7 111 29 460 2 32 5 79 0 32 508 10 159 1 16 6 95 3 48 0 5 79 6 95 18 288 4 63 5 79 1 16 54 857 20 317 3 48 14 222 9 143 0 8 127 13 206 34 540 6 95 5 79 2 32 0000378 01126 04924 07409 02022 02656 05233 02546 02659 01853 1 00006497 02515 1 03651 007271 03097 07409 0003724 1 014 1 003888 03658 1 007271 04924 03097 07628 0115 1 03097 09302 00003269 01146 08424 03544 006684 01179 01657 002333 05378 03097 1 3rd minute Chest tightness Palpitation Abdominal pain Dyspnea Diarrhea Nausea Headache Dizziness Neck pain Weakness Flush 10th minute Chest tightness Palpitation Abdominal pain Dyspnea Diarrhea Nausea Headache Dizziness Neck pain Weakness Flush 20th minute Chest tightness Palpitation Abdominal pain Dyspnea Diarrhea Nausea Headache Dizziness Neck pain Weakness Flush Any time Chest tightness Palpitation Abdominal pain Dyspnea Diarrhea Nausea Headache Dizziness Neck pain Weakness Flush Age b 65 n 63 46 730 21 333 3 48 8 127 6 95 0 5 79 11 175 22 349 4 63 2 32 2 32 41 651 15 238 1 16 10 159 4 63 0 6 95 9 143 21 333 4 63 4 63 1 16 30 476 11 175 1 16 2 32 2 32 0 5 79 8 127 13 206 4 63 4 63 1 16 47 746 22 349 4 63 12 190 8 127 0 9 143 13 206 24 381 5 79 4 63 3 48 Age 65 n 75 38 507 5 67 1 13 5 67 4 53 0 0 5 67 29 387 1 13 1 13 1 13 37 493 9 120 1 13 9 120 3 40 0 1 13 4 53 24 320 1 13 2 27 0 26 347 6 89 1 13 5 67 2 27 0 2 27 3 40 17 227 4 53 3 40 0 49 653 12 160 1 13 13 173 4 53 0 2 27 8 107 35 467 5 67 3 40 1 13 p value 001226 0000162 04924 03598 05378 004257 008804 07817 02656 08785 08785 009175 01101 1 0682 08126 007271 01334 1 02656 05237 09302 01709 01543 1 0588 1 03097 01179 09354 1 08126 09302 03206 001774 02656 09692 02201 02818 01657 04003 1 08126 04924 The halflife dipyridamole approximately 3045 min 12 In study median duration persistent symptoms 36 min Dura tion symptoms signiﬁcantly different gender age group In study population frequent symptom dizziness 428 patients Most symptoms Grade 1 suffered severe dizziness Grade 3 A study Takeishi et al revealed similar results incidence dizziness dypiridamolestress MPI 51 17 In contrast Colarinha et al showed 13 individuals 140 patients 93 undergoing Table 5 Number percentage symptomatic patients 3 10 20 min different life style groups Weekly exercise b3 times Weekly exercise N3 times p value 3rd minute 10th minute 20th minute Any time 47 603 44 564 33 423 53 679 37 617 34 567 23 383 43 717 1 1 07669 07764 Fig 3 For patients symptoms 3 min persistence shown KaplanMeier curve There difference genders 18 SD Lee et al IJC Heart Vasculature 14 2017 1419 Table 6 List patients Grade 3 symptoms Gender Age Major symptoms Associated symptoms Treatment Timing resolution 1 M 6 F 31 F 33 M 35 M 55 F 74 F 60 70 55 82 46 Weakness 60 63 Chest tightness Dyspnea Dizziness grade 2 Chest tightness abdominal pain Nausea aminophylline grade 3 20th minute Chest tightness Aminophylline 13th minute 20th minute Aminophylline 17th minute 20th minute Aminophylline 12th minute 20th minute Aminophylline 19th minute 20th minute 26th minute Aminophylline 18th minute 20th minute Chest tightness Grade 1 dizziness grade 1 ﬂush Grade 2 Aminophylline 25th minute 25th minute Chest tightness headache Nausea 5 Conclusion Our study reveals dipyridamole use MPS generally safe Women younger people tended higher risk adverse effects However trend elderly higher risk dizziness younger people Duration adverse effects sig niﬁcantly different gender age Conﬂicts No Acknowledgement No References 1 2014 Statistics causes death Ministry Health Welfare Republic China 2015 2 SD Fihn JM Gardin J Abrams K Berra JC Blankenship AP Dallas PS Douglas JM Foody TC Gerber AL Hinderliter SB King PD Kligﬁeld HM Krumholz RYK Kwong MJ Lim JA Linderbaum MJ Mack MA Munger RL Prager JF Sabik LJ Shaw JD Sikkema CR Smith SC Smith JA Spertus SV Williams ACCFAHAACPAATSPCNASCAISTS guideline diagnosis management patients stable ischemic heart disease report American College Cardiology FoundationAmerican Heart Association Task Force Practice Guide lines American College Physicians American Association Thoracic Sur gery Preventive Cardiovascular Nurses Association Society Cardiovascular Angiography Interventions Society Thoracic Surgeons J Am Coll Cardiol 60 2012 e44e164 httpdxdoiorg101016jjacc201207013 3 B Hesse K Tägil A Cuocolo C Anagnostopoulos M Bardiés J Bax F Bengel E Busemann Sokole G Davies M Dondi L Edenbrandt P Franken A Kjaer J Knuuti M Lassmann M Ljungberg C Marcassa PY Marie F McKiddie M OConnor E Prvulovich R Underwood B EckSmit EANMESC procedural guide lines myocardial perfusion imaging nuclear cardiology Eur J Nucl Med Mol Imaging 32 2005 855897 httpdxdoiorg101007s002590051779y 4 RC Hendel DS Berman MF Di Carli PA Heidenreich RE Henkin PA Pellikka GM Pohost KA Williams American College Cardiology Foundation Appropriate Use Criteria Task Force American Society Nuclear Cardiology American College Radiology American Heart Association American Society Echocardiology Society Cardiovascular Computed Tomography Society Cardiovascular Magnetic Res onance Society Nuclear Medicine ACCFASNCACRAHAASESCCTSCMRSNM 2009 Appropriate Use Criteria Cardiac Radionuclide Imaging A Report American College Cardiology Foundation Appropriate Use Criteria Task Force American Society Nuclear Cardiology American College Radiology American Heart Association American Society Echocardiography So ciety Cardiovascular Computed Tomography Society Cardiovascular Mag netic Resonance Society Nuclear Medicine J Am Coll Cardiol 53 2009 22012229 httpdxdoiorg101016jjacc200902013 5 SW Dubrey JB Bomanji MI Noble RF intravenous dipyridamole thallium myocardial perfusion imaging experience 435 patients Nucl Med Commun 14 1993 303309 Jewkes Safety 6 AM Meyers L Topham J Ballow D Totah R Wilke Adverse reactions dipyridamole patients undergoing stressrest cardiac perfusion testing J Nucl Med Technol 30 2002 2124 7 S Ando T Ashihara H Ando W Mitsuoka H Tagawa T Fukuoka Y Higuchi T Fukuyama Safety accuracy dipyridamole thallium myocardial scintigraphy elderly patients Jpn Heart J 34 1993 245254 8 J Lette JL Tatum S Fraser DD Miller DD Waters G Heller EB Stanton HS Bom J Leppo S Nattel Safety dipyridamole testing 73806 patients multicenter dipyridamole safety study J Nucl Cardiol Off Publ Am Soc Nucl Cardiol 2 1995 317 9 H Javadi M Shariati M Mogharrabi IN Asli S Jallalat A Hooman M Seyedabadi M Assadi The association dipyridamole effects hemodynamic Fig 4 For patients symptoms 3 min persistence shown KaplanMeier curve There difference genders dypiridamolestress MPI experienced dizziness 16 The variation resulted different awareness levels The second frequent symptom chest tightness ac cumulated incidence 246 It higher prior studies ranging 068 164 56131516 lower results Takeishi et al 17 Most patients suffered mild chest tightness 12 patients 87 chest tightness greater equal Grade 2 people 29 Grade 3 chest tightness Dipyridamoleinduced chest tightness corre lated severe coronary artery disease 17 According data females greater potential experience adverse effects Table 3 Fig 2 This phenomenon revealed prior study 6818 Our data revealed women higher accu mulated risk symptoms However statistically signiﬁ difference dizziness 10 min similar results Kong et al 18 Prior reports adenosineinduced adverse effects higher women 1921 The gender difference clear possibly related different fattomuscle ratio 18 In study population younger subjects greater potential adverse effects dizziness Table 4 A report Lette et al revealed frequency dipyridamoleinduced ef fects patients older 70 8 Adenosinerelated effects occur frequently younger people 22 Our data shows compared older 65 younger people higher risk symptoms dizziness There signiﬁcant difference chest tightness nausea age groups 3 min The limitation study includes retrospective study design missing data 246 relatively small population Due issues record symptom onset 20 min dipyridamole injection delayed ad verse effects evaluated SD Lee et al IJC Heart Vasculature 14 2017 1419 19 parameters ECG ﬁndings scintigraphy outcomes J Nucl Med Technol 38 2010 149152 httpdxdoiorg102967jnmt109072629 10 National Cancer Institute Common Terminology Criteria Adverse Events v40 2009 11 JA Leppo Dipyridamole myocardial perfusion imaging J Nucl Med Off Publ Soc Nucl Med 35 1994 730733 12 SG Johnson S Peters Advances pharmacologic stress agents focus regadenoson J Nucl Med Technol 38 2010 163171 httpdxdoiorg10 2967jnmt109065581 13 AP Ignaszewski LX McCormick PG Heslip AJ McEwan DP Humen Safety clinical utility combined intravenous dipyridamolesymptomlimited exercise stress test thallium201 imaging patients known suspected coronary artery disease J Nucl Med Off Publ Soc Nucl Med 34 1993 20532061 14 NG Uren JA Melin B De Bruyne W Wijns T Baudhuin PG Camici Relation tween myocardial blood ﬂow severity coronaryartery stenosis N Engl J Med 330 1994 17821788 httpdxdoiorg101056NEJM199406233302503 15 A Meyers L Topham J Ballow D Totah R Wilke Age perfusion test results dipyridamole reaction Radiol Technol 73 2002 409414 16 P Colarinha L Salgado EP Sá F Matias M Adão JF Correia MR Vieira Pharmacological stimulation dipyridamole thallium201 myocardial perfu sion scintigraphy study secondary effects Rev Port Cardiol Orgão Of Soc Port Cardiol Port J Cardiol Off J Port Soc Cardiol 15 1996 131136 100 17 Y Takeishi I Tonooka M Meguro H Hoshi I Masakane K Ikeda K Tsuiki S Yasui The relationship chest pain thallium201 scintigraphy dipyridamole myocardial ischemia Jpn Circ J 55 1991 465472 18 BA Kong L Shaw DD Miller BR Chaitman Comparison accuracy detecting coronary artery disease sideeffect proﬁle dipyridamole thallium201 myo cardial perfusion imaging women versus men Am J Cardiol 70 1992 168173 19 GS Thomas NV Prill H Majmundar RR Fabrizi JJ Thomas C Hayashida S Kothapalli JL Payne MM Payne MI Miyamoto Treadmill exercise adeno sine infusion safe results fewer adverse reactions improves myocardial perfusion image quality J Nucl Cardiol Off Publ Am Soc Nucl Cardiol 7 2000 439446 httpdxdoiorg101067mnc2000108030 20 MD Cerqueira MS Verani M Schwaiger J Heo AS Iskandrian Safety proﬁle adenosine stress perfusion imaging results Adenoscan multicenter trial registry J Am Coll Cardiol 23 1994 384389 21 SM Mohiuddin CK Ravage DJ Esterbrooks BD Lucas DE Hilleman The compar ative safety diagnostic accuracy adenosine myocardial perfusion imaging women versus men Pharmacotherapy 16 1996 646651 22 NY Poyraz E Özdemir BM Poyraz Z Kandemir M Keskin Ş Türkölmez Predictors diagnostic signiﬁcance adenosine related effects myo cardial perfusion SPECTCT imaging Mol Imaging Radionucl Ther 23 2014 8995 httpdxdoiorg104274mirt85057